- Home
- BR vs ONC Comparison
BR vs ONC Comparison
Compare BR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BR
- ONC
- Stock Information
- Founded
- BR 1962
- ONC 2010
- Country
- BR United States
- ONC Switzerland
- Employees
- BR N/A
- ONC N/A
- Industry
- BR Business Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- BR Consumer Discretionary
- ONC Health Care
- Exchange
- BR Nasdaq
- ONC Nasdaq
- Market Cap
- BR 28.2B
- ONC 26.9B
- IPO Year
- BR 2007
- ONC N/A
- Fundamental
- Price
- BR $235.10
- ONC $250.30
- Analyst Decision
- BR Buy
- ONC Strong Buy
- Analyst Count
- BR 7
- ONC 9
- Target Price
- BR $250.83
- ONC $325.56
- AVG Volume (30 Days)
- BR 472.1K
- ONC 345.1K
- Earning Date
- BR 08-05-2025
- ONC 08-06-2025
- Dividend Yield
- BR 1.50%
- ONC N/A
- EPS Growth
- BR 13.70
- ONC N/A
- EPS
- BR 6.66
- ONC N/A
- Revenue
- BR $6,768,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- BR $8.99
- ONC $869.15
- Revenue Next Year
- BR $4.81
- ONC $19.07
- P/E Ratio
- BR $35.32
- ONC N/A
- Revenue Growth
- BR 5.72
- ONC 51.16
- 52 Week Low
- BR $198.71
- ONC $146.21
- 52 Week High
- BR $247.01
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- BR 42.06
- ONC N/A
- Support Level
- BR $236.40
- ONC N/A
- Resistance Level
- BR $240.47
- ONC N/A
- Average True Range (ATR)
- BR 4.56
- ONC 0.00
- MACD
- BR -0.52
- ONC 0.00
- Stochastic Oscillator
- BR 16.06
- ONC 0.00
About BR Broadridge Financial Solutions Inc.
Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two segments: investor communication solutions and global technology and operations.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.